Chalazion

1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
loteprednol etabonate/tobramycin opthalmic suspensionPhase 41 trial
Active Trials
NCT00420628Completed108Est. Jun 2009
Lumenis
LumenisAustralia - Chatswood
2 programs
OptiLIGHTN/A1 trial
Sham IPLN/A1 trial
Active Trials
NCT07039461Terminated4Est. Dec 2025
NCT07405138Not Yet Recruiting40Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch + Lombloteprednol etabonate/tobramycin opthalmic suspension
LumenisSham IPL
LumenisOptiLIGHT

Clinical Trials (3)

Total enrollment: 152 patients across 3 trials

NCT00420628Bausch + Lombloteprednol etabonate/tobramycin opthalmic suspension

Pediatric Zylet Safety and Efficacy Study

Start: Nov 2006Est. completion: Jun 2009108 patients
Phase 4Completed

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

Start: Feb 2026Est. completion: Dec 202640 patients
N/ANot Yet Recruiting

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

Start: Sep 2025Est. completion: Dec 20254 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space